Final Report Summary - LUNELY (ALK as a common target for the pathogenesis and therapy in lymphoma, lung carcinoma and neuroblastoma)
All these data have been validated in the pre-clinical settings of our models. Next important steps will be to move them into clinical trial for future therapeutic use.